David A. Siegel Astria Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

  • $41.3 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023
SELL
$8.33 - $13.72 $339,031 - $558,404
-40,700 Reduced 23.43%
133,034 $1.11 Million
Q1 2023

May 15, 2023
BUY
$11.2 - $15.79 $1.06 Million - $1.49 Million
94,600 Added 119.54%
173,734 $2.31 Million
Q4 2022

Feb 14, 2023
BUY
$7.44 - $14.89 $588,756 - $1.18 Million
79,134 New
79,134 $1.18 Million

Others Institutions Holding ATXS

# of Institutions
110
Shares Held
48.6M
Call Options Held
48K
Put Options Held
9.3K
View Full List

About Astria Therapeutics, Inc.

ATXS Quotes by TradingView
  • Ticker ATXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,178,000
  • Market Cap $112M
  • Description
  • Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...
More about ATXS
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email